Cinven buys Mercury Pharma from HgCapital for $732 mln
LONDON Aug 17 (Reuters) - Investor HgCapital has sold British pharmaceutical company Mercury Pharma to private equity firm Cinven for 465 million pounds ($732 million).
"The realisation of Mercury Pharma marks the continued development of HgCapital's investment focus in the healthcare sector," said HgCapital's head of healthcare, Philipp Schwalber, in a statement on Friday.
"We continue to seek out businesses that enjoy niches of secular growth despite the challenges facing much of the healthcare space," he said.
HgCapital bought the 25-year-old pharmaceutical firm, which sells niche prescription off-patent products in the UK, Ireland and the Netherlands, in 2009.
It said its listed investment trust HgCapital Trust expects to receive 35.4 million pounds in cash on the sale completion and further potential proceeds of 1 million pounds over the next 30 months.
- Tweet this
- Share this
- Digg this
- Plague in Madagascar has killed 40 people out of 119 cases -WHO
- Widespread flooding ahead for snowy western New York: officials |
- U.S., Iran discussing new ideas to break nuclear impasse - sources
- Pakistani family sentenced to death over "honour killing" outside court
- Video streaming service Aereo files for bankruptcy
Prime Minister Narendra Modi has a long list of pro-growth measures to implement over the next four months, but time may have already run out to breathe enough life into the economy to meet the tough 2014/15 fiscal deficit target without cuts. Article